Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC).

Trial Profile

Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as Second Line Therapy in Patients With Stage IIIB or Stage IV Non Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2014

At a glance

  • Drugs Sagopilone (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Bayer added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top